← Back to headlines
FDA Accepts Gilead's sNDA for Weekly Yeztugo HIV Pill
The U.S. Food and Drug Administration (FDA) has accepted Gilead's supplemental New Drug Application (sNDA) for its weekly Yeztugo HIV pill.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
